Contineum Therapeutics, Inc.
CTNM
$4.95
$0.337.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -41.86% | -13.96% | -7.03% | -8.34% | -24.28% |
| Total Depreciation and Amortization | 20.97% | 3.33% | -1.64% | 64.86% | -13.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.12% | 160.70% | 521.70% | 158.24% | 36.81% |
| Change in Net Operating Assets | 27.26% | 1,209.09% | -176.00% | 109.86% | -349.33% |
| Cash from Operations | -65.38% | 27.41% | -6.57% | 25.50% | -99.07% |
| Capital Expenditure | -102.44% | 31.09% | 19.05% | 52.43% | -1,304.55% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.38% | 22.33% | -536.81% | -4.94% | 123.66% |
| Cash from Investing | 68.90% | 22.41% | -545.53% | -3.31% | 122.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,838.46% | -99.99% | 88,608.20% | 144.00% | -39.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | 59.18% | -- |
| Cash from Financing | 4,838.46% | -99.99% | 602,122.22% | 94.39% | -103.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.86% | -159.61% | 8,160.98% | 136.99% | 94.23% |